Gout Treatment
For acute gout, treat immediately with corticosteroids as first-line therapy (prednisolone 35 mg daily for 5 days), NSAIDs, or low-dose colchicine (1.2 mg followed by 0.6 mg one hour later); for long-term management, initiate urate-lowering therapy with allopurinol only in patients with recurrent attacks (≥2 per year), tophi, chronic kidney disease, or urolithiasis, titrating to serum urate <6 mg/dL while providing prophylaxis with low-dose colchicine for at least 6 months. 1, 2
Acute Gout Treatment
First-Line Options (Choose Based on Contraindications)
Corticosteroids should be your default choice because they are equally effective as NSAIDs with fewer adverse effects and lower cost 1. Use prednisolone 35 mg daily for 5 days 1. Avoid in patients with systemic fungal infections or uncontrolled diabetes.
NSAIDs are equally effective—indomethacin has no advantage over naproxen or ibuprofen despite traditional preference 1. Contraindicated in renal disease, heart failure, or cirrhosis. Always co-prescribe proton pump inhibitors 2.
Low-dose colchicine (1.2 mg loading dose, then 0.6 mg one hour later) is as effective as high-dose regimens with 77% fewer gastrointestinal side effects 1. Must start within 12 hours of symptom onset 2. Critical contraindication: Do not use with CYP3A4 inhibitors (clarithromycin, cyclosporin) or in severe renal/hepatic impairment 1, 2.
Key Principles for Acute Management
- Educate patients to self-treat at first warning symptoms 2—early treatment is more effective
- Intra-articular corticosteroid injection is appropriate for monoarticular flares 2
- IL-1 blockers (anakinra, canakinumab) are reserved for patients with contraindications to all three first-line agents 2
Long-Term Management: When to Start Urate-Lowering Therapy
Do NOT Start ULT After First Attack
Avoid initiating urate-lowering therapy after a single gout attack or in patients with infrequent attacks (<2 per year) 1. The benefits of long-term therapy in these patients are unproven, and many will have no recurrences.
Indications to Start ULT (Any of the Following)
- ≥2 gout attacks per year
- Presence of tophi
- Chronic kidney disease
- Urolithiasis (kidney stones)
- Radiographic joint damage
- Young age at presentation (<40 years)
- Very high serum urate (>8 mg/dL or >476 µmol/L) 1, 2
Urate-Lowering Therapy Protocol
Allopurinol is first-line, starting at low dose and titrating gradually to achieve serum urate <6 mg/dL (<360 µmol/L) 2, 3. For patients with tophi, target <5 mg/dL for faster crystal dissolution 3.
Febuxostat (40 mg daily) is equally effective at lowering urate but costs more and causes abdominal pain, diarrhea, and musculoskeletal pain 1. Important safety concern: Febuxostat is associated with increased all-cause and cardiovascular mortality compared to allopurinol 4, 5—avoid routine use.
Mandatory Flare Prophylaxis During ULT Initiation
You must provide prophylaxis for at least 6 months when starting urate-lowering therapy 1, 2. ULT does not reduce flares in the first 6 months and may actually trigger attacks 1.
Prophylaxis options:
- Colchicine 0.5-1 mg daily (reduce dose in renal impairment; avoid with CYP3A4 inhibitors or statins due to neurotoxicity/myopathy risk) 2
- Low-dose NSAIDs if colchicine contraindicated 2
Continuing prophylaxis beyond 8 weeks is more effective than shorter durations 1.
Patient Education and Lifestyle Modifications
Every patient must understand that gout is curable with lifelong urate-lowering to target levels 2. This "treat-to-target" approach eliminates crystal deposits and prevents flares.
Specific lifestyle recommendations:
- Weight loss if overweight
- Avoid beer, spirits, and sugar-sweetened beverages
- Limit meat and seafood intake
- Encourage low-fat dairy products
- Avoid heavy meals
- Regular exercise 2
Comorbidity Screening
Screen all gout patients systematically for:
- Renal impairment
- Cardiovascular disease (coronary disease, heart failure, stroke, peripheral arterial disease)
- Metabolic syndrome components (obesity, hyperlipidemia, hypertension, diabetes)
- Smoking status 2
These comorbidities must be managed as integral parts of gout treatment, not separately.
Common Pitfalls to Avoid
- Do not use indomethacin preferentially—it has no efficacy advantage and the same side effect profile as other NSAIDs 1
- Do not start ULT during an acute flare—wait until the attack resolves, then initiate with prophylaxis 2
- Do not forget prophylaxis when starting ULT—this is the most common cause of treatment failure and patient frustration
- Do not combine colchicine with strong CYP3A4 inhibitors—this causes severe toxicity 1, 2
- Do not rely solely on serum urate for diagnosis during acute flares—levels may be normal during attacks 6